Oncology Nurses Play Key Role as KRAS-Targeted Therapies Expand Across Cancer Care

In an interview with Oncology Nursing News, Dr. Asfar Azmi, professor of oncology at Wayne State University School of Medicine, highlighted the growing role oncology nurses play as KRAS-targeted therapies continue to evolve. While first-generation RAS inhibitors such as sotorasib and adagrasib are already approved for non-small cell lung cancer and in combination settings for colorectal cancer, the treatment landscape is rapidly expanding.

Dr. Azmi emphasized that oncology nurses are often on the front lines of patient education and can play a critical role in guiding patients who have undergone genomic testing. For patients with KRAS mutations, nurses can help identify potential eligibility for clinical trials and encourage discussions around emerging targeted therapies.

With anticipated FDA approvals on the horizon, particularly for newer agents in pancreatic cancer, staying informed is increasingly important. Nurses and oncology practitioners should be aware of these developments so they can communicate that chemotherapy may not be the only available option and that newer therapies and trials could offer additional opportunities.

Ultimately, Dr. Azmi stressed that keeping up to date with the latest research and sharing accurate information with patients can directly impact care decisions. As treatment options expand, informed oncology nurses will continue to play a key role in helping patients navigate a more personalized and evolving cancer care landscape.